ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Rating of "Buy" from Analysts

Key Points

• ICU Medical, Inc. has received an average recommendation of "Buy" from five research firms, with one strong buy, three buy ratings, and one hold rating.
• The average 12-month target price among analysts for ICU Medical is $179.00, while Raymond James recently lowered its price target from $187.00 to $180.00.
• CEO Vivek Jain significantly increased his stake in ICU Medical by acquiring 21,929 shares at an average cost of $112.84 per share, boosting his ownership by 20.26%.

Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) have earned an average recommendation of "Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $181.00.

ICUI has been the subject of several research reports. Raymond James Financial dropped their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a report on Friday, August 8th. Piper Sandler lifted their price target on ICU Medical from $145.00 to $153.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th.

Insiders Place Their Bets

In related news, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the purchase, the chief executive officer directly owned 130,149 shares in the company, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David C. Greenberg acquired 1,200 shares of the stock in a transaction on Wednesday, August 27th. The shares were bought at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the purchase, the director owned 7,960 shares in the company, valued at approximately $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On ICU Medical

Hedge funds have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. bought a new position in ICU Medical during the 2nd quarter worth $38,000. GAMMA Investing LLC increased its stake in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 153 shares during the period. Blue Trust Inc. increased its stake in shares of ICU Medical by 23.0% in the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 150 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after purchasing an additional 101 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of ICU Medical in the 2nd quarter valued at $177,000. Institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

Shares of ICUI traded down $4.65 during mid-day trading on Tuesday, reaching $130.38. The company's stock had a trading volume of 240,362 shares, compared to its average volume of 272,881. ICU Medical has a 1-year low of $107.00 and a 1-year high of $196.26. The stock has a market cap of $3.22 billion, a P/E ratio of -85.78 and a beta of 0.86. The business has a 50-day simple moving average of $126.23 and a two-hundred day simple moving average of $133.60. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business's revenue was down 8.0% on a year-over-year basis. During the same period last year, the firm posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities research analysts anticipate that ICU Medical will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.